U lcerative colitis (UC) is a chronic, disabling inflammatory bowel disease (IBD) that generally begins in young adulthood and lasts throughout life. 1 Although its incidence and prevalence have stabilized in high incidence areas such as Western Europe and North America, it continues to rise in low incidence areas such as Eastern Europe, Asia, and much of the developing world. 1, 2 Besides significantly impacting quality of life and work productivity because of debilitating symptoms, UC is also associated with an increased risk of colorectal cancer (CRC). 1, 3, 4 A detailed knowledge of the natural history of UC is essential to understand disease evolution, evaluate the impact of treatment strategies, identify predictors for disabling disease, and provide comprehensive information to patients to facilitate shared decision-making. 5, 6 In contrast to randomized controlled trials that evaluate specific interventions in a limited set of highly selected patients during a short pre-defined period, populationbased observational cohort studies evaluate an entire population in defined geographic area during an extended period of time. They are ideal to inform natural history of disease and also avoid selection biases associated with referral center cohort studies. 5, 7, 8 Hence, to comprehensively understand the natural history of adult-onset UC, we conducted a systematic literature review of population-based inception cohort studies with extended follow-up (>1 year). We evaluated several UC-related outcomes including (1) disease phenotype, (2) disease activity and complications, (3) use of UC-related medications, (4) malignancy, (5) morbidity and mortality, and (6) extraintestinal complications. In addition, we systematically reviewed clinical, biochemical, and/or endoscopic predictors of natural history of UC.
The use of systematic reviews may facilitate the identification of appropriately designed studies and a comprehensive evaluation of divergent results, while delineating topics that require further research.
Materials and Methods

Literature Search
We conducted a systematic literature search of English and non-English language publications in MEDLINE (source PUBMED, 1935 to March 31, 2016) to identify published population-based studies in patients with UC. We searched for the following terms: ("Inflammatory bowel diseases" OR "ulcerative colitis") AND ("natural history" OR "population-based" OR "longterm outcome" OR "long-term follow-up" OR "inception cohort" OR "relapse" OR "disease activity" OR "extraintestinal manifestations" OR "corticosteroids" OR "immunosuppressants" OR "anti-TNF" OR "surgery" OR "colectomy" OR "mortality" OR "cancer" OR "hospitalization" OR "predictors"). A single reviewer screened and identified relevant studies for inclusion, following an a priori established protocol. In addition, a recursive search of relevant systematic reviews was also performed. The reference lists of relevant articles were also reviewed. Data extraction was carried out by using a standardized data collection form by a single reviewer and confirmed by a second reviewer independently.
Inclusion and Exclusion Criteria
We included only population-based inception cohort studies of patients with adult-onset UC (18 years at diagnosis), on the basis of standard clinical, endoscopic, and/or histologic criteria through medical record review, with minimum 1-year follow-up, describing the natural history of UC in terms of the following outcomes: disease phenotype, disease activity, complications, diseaserelated medications, malignancies, morbidity, mortality, and/or extraintestinal complications.
We excluded the following studies: (1) reporting only incidence and/or prevalence of UC, (2) reporting phenotype, disease complications, and/or treatment only at time of diagnosis, (3) population-based studies that relied on administrative codes for UC diagnosis without medical record review, (4) reporting only on IBD without separate data on UC per se, (5) non-inception cohort studies that included patients with prevalent UC, and (6) studies focused on patients with pediatric-onset (<18 years) or elderly-onset (>60 years) UC. Often one population-based cohort reported several pertinent outcomes, in which case we only included the most recent study with unique outcomes with the longest follow-up.
Outcomes of Interest
To comprehensively describe natural history of UC, we studied several UC-related outcomes including (1) disease phenotype (including disease location, proximal extension, and change in diagnosis); (2) disease activity and complications (including rates of relapse, hospitalization, surgery, and postoperative complications); (3) use of UC-related medications (including mesalamine, corticosteroids, immunomodulators, and anti-tumor necrosis factor [TNF]-a agents); (4) malignancy (including CRC and extraintestinal cancers); (5) morbidity and mortality; and (6) extraintestinal complications (including extraintestinal disease manifestations, anemia, osteoporosis, and venous and arterial thromboembolic events). The Montreal classification was used to classify and compare the phenotype between the various studies. When data were available, we attempted to compare and contrast differences in disease course between patients diagnosed in the prebiologic (before 2005) and biologic eras (after 2005). In addition, we systematically reviewed clinical, biochemical, and/or endoscopic predictors of natural history of UC.
Outcomes at different time points were generally reported in studies either as point prevalence (at a particular time point) or as cumulative probability (during a particular time period). Because of differences in reporting patterns, we opted not to perform a metaanalysis, but instead we systematically reported these findings by using median and interquartile range (IQR) or range or as preferred summary measures.
Results
Through a systematic literature review, we identified 60 studies reporting on 17 population-based cohorts. Key characteristics of these cohorts and corresponding studies are detailed in Table 1 . These included 12 European cohorts, 2 North American cohorts, and 2 Asia-Oceania cohorts. Patients were recruited from 1940 to 2014. Sample sizes of these studies ranged from 63 to 3117 patients (total, 15,316), and median follow-up ranged from 1 to 20 years. Salient aspects of study methodology of each population-based cohort are detailed in Supplementary  Table 1. Main results of each evaluated outcome are  summarized in Tables 2, 3 , and 4 and Figure 1 .
Disease Phenotype
Disease extension. At diagnosis, the majority of patients had left-sided colitis (median, 40.1%; IQR, 32.6%-44.6%); 30.5% (29.8%-32.6%) and 29.4% (25.3%-34.7%) were diagnosed with extensive colitis and proctitis, respectively. [9] [10] [11] [12] [13] [14] [15] [16] [17] Overall rates of disease extension were comparable across cohorts, regions, and over time (including the pre-biologic and biologic eras) ( Table 2) . Rate of progression from proctitis to left-sided colitis was 28%-30%, and to extensive colitis it was 14%-16%; rate of progression from left-sided colitis to extensive colitis was 21%-34%. 9, 10, 18 Overall rates of progression ranged from 12% to 30%, with cumulative 5-year risk of progression of approximately 13%. 10, 13, 14 At the end of follow-up, leftsided colitis (44%-53%) was the most common site of disease involvement, followed by extensive colitis (24%-28%) and proctitis (22%-28%). Extraintestinal manifestations (EIMs) (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.4-9.3) and elevated C-reactive protein (CRP) both at diagnosis and at 5 years of follow-up were significantly associated with extensive disease. 13, 15 Change of diagnosis. In the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD) cohort, the original diagnosis of UC remained unchanged in 98% of cases after 4 years of follow-up 19 ; in 1% of patients, the diagnosis was changed to Crohn's disease and in another 1% to indeterminate colitis. In the South Limburg cohort, the diagnosis of UC was changed in 3% of patients after a median follow-up of 7 years. 16 
Disease Activity and Complications
Disease relapse. In the 10-year follow-up study of the IBSEN cohort, 4 different profiles of disease activity were reported by patients: remission or mild severity after initial period of high activity (55%), chronic intermittent symptoms (37%), chronic continuous symptoms (6%), and increase in activity after period of low activity (1%). 18 In studies evaluating changes in disease activity within the first 1-2 years of diagnosis, most studies observed improvement in disease activity in 50%-70% of patients. 14, 20, 21 In the Uppsala cohort, 50% of patients remained in remission within the first year after initial disease flare, 43% of patients experienced relapse, and 5% had chronic symptoms without remission. 21 Similarly, in the Asia-Pacific cohort during the 1 year after diagnosis, 65% of patients were in clinical remission (UC Simple Clinical Colitis Activity Index [SCCAI], 2), 18% had mild to moderate disease (SCCAI, 3-4), and 17% had severe disease (SCCAI, 5), respectively.
14 On longer follow-up, rates of remission remained stable. In the EC-IBD cohort 19 after 4 years of follow-up, half of patients described complete relief of their symptoms. Cumulative risk of relapse ranged from 67% to 83% at 10 years (median, 70.0%; IQR, 68.5%-76.5%). 19, 21, 22 There has been limited comparison of disease activity trends between the pre-biologic and biologic eras, although there seems to be a shift toward improved early disease course, which is perhaps related to availability and early adoption of more effective therapies. In a cohort of patients diagnosed in Copenhagen County between 1962 and 1993, disease course was characterized as indolent, moderate, or aggressive in 13%, 73%, and 14% of patients, respectively, within the first 5 years of diagnosis; in the same region in a cohort of patients diagnosed between 2003 and 2004, early disease activity was characterized as mild in 76% and moderate to severe in 24%. 23, 24 Young age at disease onset (hazard ratio [HR], 1.3; 95% CI, 1.0-1.6), female sex (HR, 1.4; 95% CI, 1.1-1.7), and high level of education (HR, 1.4; 95% CI, 1.1-1.8) have been associated with disease relapse, whereas smoking may be protective (HR, 0.7; 95% CI, 0.6-0.9). 9, 16, 21 Conflicting data on the association between serologic markers and risk of relapse were observed 25, 26 (Table 5 ). Hospitalization. Almost half of the patients with UC require hospitalization at some point during disease course, with 1-, 5-, and 10-year cumulative probabilities ranging from 17% to 29%, 29% to 54%, and 39% to 66%, respectively; 10%-15% may be hospitalized at time of diagnosis. 11, 12, 20, 27 Among patients who are hospitalized once, cumulative probability of rehospitalization 1, 5, and 10 years after index hospitalization ranges from 24%, 51% to 56%, and 59% to 75%, respectively.
11,12,20,27 Overall, the rate of hospitalization may be declining; in an Olmsted County cohort, rate of Table 3 . Disease extent at diagnosis (HR, 1.8; P ¼ .02), need for corticosteroids (HR, 2.0; P < .001), immunomodulators (HR, 1.6; P ¼ .038), and/or anti-TNF agents (HR, 2.3; P < .001) have been associated with an increased risk of UC-related hospitalization 12, 27 ; early need for hospitalization (<90 days after diagnosis) was an independent predictor for future hospitalization (HR, 1.5; 95% CI, 1.0-2.4). 12 Surgery. Risk of colectomy in adults with UC has been extensively studied and is summarized in Supplementary  Figure 1 . In an early report of colectomy from the Stockholm County cohort in patients diagnosed between 1966 and 1984, cumulative colectomy rate at 5, 10, and 25 years after diagnosis was 20%, 28%, and 45%, respectively. 28 Subsequent studies have reported lower rates of colectomy, with 1-, 5-, 10-, and 20-year cumulative colectomy rates ranging from 0.5% to 6%, 3% to 13%, 8.5% to 19%, and 11% to 20%, respectively. [10] [11] [12] 14, 17, 18, 20, 23, [29] [30] [31] [32] [33] A recent meta-analysis of population-based studies observed a cumulative risk of surgery in adults of 4.4%, 10.1%, and 14.6%, respectively, 1, 5, and 10 years after UC diagnosis, with a significant decrease over time. 34 In a contemporary Copenhagen County cohort of patients diagnosed between 2003 and 2004, cumulative risk of colectomy at 5 years was 10% 23 ; similarly, in a recently established Oceania cohort, less than 2% of patients in Asia and 6% in Australia underwent a colectomy after median 1.5 years of follow-up. 11, 14 In the Dutch population-based South Limburg cohort, patients diagnosed with UC between 1991 and 1997 had an early colectomy rate (within 6 months) of 1.5%, compared with a rate of 0.5% in a contemporary cohort from 2006 to 2010; late colectomy rates in these cohorts were similar (1991-1997 vs 2006-2010: 4% vs 3.6%). 35 The indication for colectomy appears to have changed over time. In Olmsted County among colectomies performed before 1990, 90% were performed for medically refractory disease, 5% for fulminant colitis, and 5% for colorectal neoplasia. In contrast, among surgeries performed after 1990, 56% were performed for medically refractory disease, 26% for fulminant colitis, and 12% for colorectal neoplasia. The types of surgery were total protocolectomy with ileal pouch-anal anastomosis in 54%, total proctocolectomy with end ileostomy in 33%, and subtotal colectomy and ileostomy in 12%. 12 Disease extent consistently influences risk of colectomy (OR, 2.2; 95% CI, 1.1-4.3), with significantly higher risk in patients with extensive colitis (10-year cumulative risk, 19%), followed by left-sided colitis (8%) and ulcerative proctitis (5%). 16, 18, 20 Young age (age <40 years: OR, 2.8; 95% CI, 1.3-5.9), male gender (HR, 2.1; 95% CI, 1.3-3.5), and elevated CRP/erythrocyte sedimentation rate (ESR) (CRP 30 mg/L or ESR 30 mm/ h: OR, 3.3, 95% CI, 1.7-6.5) at diagnosis have been associated with an increased risk of colectomy. 11, 12, 21 In the IBSEN cohort, patients younger than 40 years with extensive colitis who were treated with systemic corticosteroids and had ESR 30 mm/h or CRP 30 mg/L at diagnosis had a probability of colectomy of 40% as compared with 8% for same age patient with proctitis or left-sided colitis and ESR <30 mm/h or CRP <30 mg/L at diagnosis. 36 In a Norwegian cohort, achieving endoscopic mucosal healing within 1 year of disease onset was associated with a 78% lower risk of future colectomy, as compared with continued endoscopic disease activity (relative risk, 0.2; 95% CI, 0.1-0.8). 36 However, the majority of the colectomies occurred during the first 3 months after endoscopic assessment, which limits the interpretation of long-term impact of mucosal healing in UC.
Postoperative complications. In the EC-IBD cohort, 32% of patients operated on between 1993 and 2004 developed postoperative complications without difference between acute and elective surgery, and 6% died postoperatively. 37 Among the 33 deaths observed in the 1962-1987 cohorts from Copenhagen, 19 (58%) resulted from postoperative complications. A metaanalysis of both administrative and inception population-based studies recently observed a pooled mortality rate of 0.7% and 5.3% for elective and emergent surgery, respectively, without significant decrease over time. 38 In summary, the majority of patients with UC have a mild-moderate course, generally most active at diagnosis and then in varying periods of remission or mild activity; about 14%-17% of patients may experience an aggressive course. Median cumulative risk of relapse is 70.0% (IQR, 68.5%-76.5%) by 10 years. Almost half the patients require UC-related hospitalization at some point during disease course, and among those hospitalized once, 5-year risk of re-hospitalization is about 50%. The 5-and 10-year cumulative risk of surgery is 10%-15%, and although rates of early colectomy have declined, long-term colectomy rates have generally remained stable over time; contemporary cohorts with early use of biologic agents are lacking.
Ulcerative Colitis-related Medications
No inflammatory bowel disease medications. In the Uppsala inception cohort, 97% patients were exposed to either mesalamine or steroids during the first year after diagnosis. 21 The prevalence of no IBD medications 1, 5, and 11 years after diagnosis was 26%, 32%, and 40%, respectively, in the Dutch-SL cohort. 16 Mesalamine. Approximately 88%-97% patients received mesalamine within 1 year of diagnosis 14, 20, 21 ( Table 3) . On long-term follow-up, 60%-87% of patients continued mesalamine use at 11-15 years after diagnosis, without significant change over time. 10, 16, 23 Corticosteroids. In the Copenhagen cohort, 50% of patients received corticosteroids after a median followup of 15 years. 23 Among patients with corticosteroid exposure, cumulative rates of second course of corticosteroids at 1, 5, and 10 years were 13%, 41%, and 48%, respectively, in the IBSEN cohort; however, the likelihood of steroid exposure decreases with time since UC diagnosis, with reported 1-, 5-, and 11-year point prevalence of corticosteroid use of 20%, 18%, and 12%, respectively. 16 Implications and outcomes of corticosteroid exposure were studied in the Olmsted County cohort in a prebiologic era. Faubion et al 39 observed that within 30 days of a course of corticosteroids, 54% of patients achieved complete remission, 30% were in partial remission, and 16% were non-responders; 1 year after initiation of corticosteroids, 49% were in sustained clinical remission, 22% were steroid-dependent, and 29% underwent colectomy. Among patients diagnosed between 2003 and 2004 in the Copenhagen County cohort, steroid dependency was observed in 9% of patients after follow-up of 5 years. The risk of corticosteroid exposure appears to be decreasing in the biologic era. In the same Copenhagen County cohort, exposure to corticosteroids was significantly higher in patients diagnosed between 1962 and 1987 (53%) and 1991and 1993 (56%) as compared with 2003-2004 (40%). 23 However, 5 years later, 59% of patients were exposed to corticosteroids. 10 Extensive colitis and EIMs (OR, 3.1; 95% CI, 1.7-5.5) have been significantly associated with need for corticosteroids. 13, 16 Immunomodulators. The use of immunomodulators has increased incrementally since the 1990s. 10, 16 In the pre-biologic era, the point prevalence of immunomodulator medications use at 1, 5, and 10 years after diagnosis was 5%, 12%, and 12%, respectively. 16 In contemporary cohorts, immunomodulator use has increased 2-to 3-fold, with reported use in 11%-20% at 1 year and 17%-27% by 7 years. 10, 11, 14, 20, 23, 27 In the Dutch-SL cohort, the 5-year cumulative probability of using thiopurines increased from 8% in patients diagnosed between 1991 and 1997 to 23% in patients diagnosed between 1998 and 2010. Over time, thiopurines have also been initiated earlier during disease course, from median of 23 months (1991-1997) to 10 months after UC diagnosis (2006) (2007) (2008) (2009) (2010) . 35 About 10% experienced adverse events after a median of 1 month (range, 1-24 months). 11 Likelihood of exposure to immunomodulator is significantly higher in patients with extensive colitis (HR, 2.9; 95% CI, 1.7-4.9) and EIMs (OR, 2.6; 95% CI, 1.4-4.9).
13,14
Anti-tumor necrosis factor. Limited studies have evaluated patterns of anti-TNF use in population-based cohorts. In contemporary cohorts at 1 year, 1%-5% of patients were treated with anti-TNF. 11, 14, 20, 21 More longterm results are available from Copenhagen County and Hungary, where 4% of patients have been treated with anti-TNF at 5 years and 6%-7% at 7 years. 10, 27 In the Dutch-SL cohort, the cumulative 5-year probability of anti-TNF exposure increased from 4% in patients diagnosed between 1998 and 2005 to 10% in patients diagnosed between 2006 and 2010, and the median time to initiation decreased from 44 to 12 months; 37% received combination therapy with azathioprine. 35 In the EPICOM cohort, most of the patients treated with anti-TNF (65%) had extensive colitis. Young age at time of disease onset (<40 years: HR, 2.5; 95% CI, 1.1-5.7) was associated with anti-TNF exposure. 20 To summarize, almost all patients with UC are exposed to mesalamine within 1 year of diagnosis, although 30%-40% are not on mesalamine on long-term follow-up. About 50% of patients eventually receive a treatment course of corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20% of patients) and anti-TNF (5%-10%).
Malignancies
Colorectal cancer. Since the recognition of increased risk of CRC in patients with UC in a Swedish populationbased cohort (standardized incidence ratio [SIR], 5.7; 95% CI, 4.6-7.0), 40 several studies have confirmed increased CRC rates in UC patients, with a pooled SIR of 2.4 (95% CI, 2.1-2.7), and an average 1.6% of patients are diagnosed with CRC during 14 years of follow-up 41 ( Table 4) . Cumulative probability of CRC at 10, 20, and 30 years after UC diagnosis was 0.4%-0.6%, 1.1%-5.4%, and 2.1%-7.5%, respectively. 42, 43 This risk is increased in patients with pancolitis (SIR, 2.4-14.8) and left-sided colitis (SIR, 1.4-2.8), but not in patients with proctitis. 40, [44] [45] [46] Young age at diagnosis, male sex, extensive colitis, disease duration, and concomitant primary sclerosing cholangitis have been consistently identified as risk factors of CRC. The risk of CRC was similar in users and non-users of mesalamine and thiopurines in Denmark. 30 One populationbased study suggested that CRC complicating UC is more aggressive than sporadic CRC; unadjusted overall mortality (47/100,000 py) was almost 2-fold higher as compared with patients with sporadic CRC (standardized mortality ratio, 1.8; 95% CI, 1.4-2.2). 17 Extraintestinal cancer. Population-based studies have shown no consistent increase in the risk of overall or extraintestinal cancers in patients with UC, as compared with the general population (Table 4) . 30, 42, [46] [47] [48] On metaanalysis of population-based inception cohorts, patients with UC were noted to have a lower risk of lung cancer (SIR, 0.4; 95% CI, 0.2-0.7) and overall cancers of the respiratory tract (SIR, 0.7; 95% CI, 0.5-1.0) and a higher risk of liver and biliary tract cancers (SIR, 2.6; 95% CI, 1.6-4.2) and leukemia (SIR, 2.0; 95% CI, 1.3-3.1). 49 No consistent increase in the risk of prostate or cervical cancer, melanoma, or Hodgkin's lymphoma or nonHodgkin's lymphoma was observed. 49 In the Danish North Jutland cohort, overall cancer risk was similar among women and men, across age groups, across disease localization, among smokers and non-smokers, and among ever users and never users of mesalamine and thiopurines. 30 
Morbidity and Mortality
Patient-reported outcomes, quality of life, and disability. In the Manitoba cohort, patients with UC reported high rates of fatigue and sleep difficulties, particularly those with active symptoms (67% and 72%, respectively), as compared with those with inactive UC (30% and 57%, respectively), and these rates were not significantly different than in patients with CD. 50 This high rate of fatigue was confirmed in the Dutch-SL cohort and was associated with lower quality of life. Disease activity, anemia, and female sex were independent determinants of fatigue. 51 Health-related quality of life scores generally improved from diagnosis to 1 year of disease, and baseline high Short Inflammatory Bowel Disease Questionnaire scores, limited disease extent, absence of EIMs, non-receipt of biologic therapy, and no need for surgery were predictive of superior healthrelated quality of life on follow-up. 52, 53 Overall disability burden was lower in patients with UC, as compared with patients with CD, and was associated with long-term active disease, but not IBD-related surgeries or hospitalizations. 54 In a contemporary Australian cohort, 25% of patients were classified as having disabling disease defined by at least one of the following criteria present at 12 months: >2 courses of steroids, further hospitalization after diagnosis, ongoing active disease, or colectomy.
11 Work disability, defined as all patients who had applied for or had been granted rehabilitation benefits, was evaluated in the IBSEN cohort. Patients with UC had 1.8 times higher risk of work disability (95% CI, 1.4-2.3) as compared with general population, and that rate was comparable with that seen in patients with CD. 55 Male sex, disease relapse, need for corticosteroids or surgery within 1 year of disease onset, and elevated CRP or ESR have been associated with work disability. 11, 55 Mortality. UC has not been associated with an increased mortality, as compared with the general population, except in 1 cohort. 23, [56] [57] [58] [59] [60] [61] When assessing the specific causes of death, UC may be associated with increase in the risk of gastrointestinal-related mortality, partly attributed to an increased mortality from liver diseases, and inconsistent increase in risk of CRC-related mortality and respiratory-related mortality primarily because of asthma-related deaths, despite a decrease in risk of respiratory tract cancers. Overall, there has been no increase in risk of cancer-related or cardiovascular mortality. 46, 56, [58] [59] [60] [61] [62] 
Extraintestinal Complications
Extraintestinal manifestations. Overall risk of EIMs in patients with UC ranges from 7% to 17%, probably lower as compared with patients with CD, and approximately 1% patients may present with EIMs before UC diagnosis. 13, 16, 63 Articular manifestations are the most frequently observed EIMs (8%), including peripheral arthritis (5.5%) and ankylosing spondylitis (1%), followed by cutaneous EIMs (1.3%), primary sclerosing cholangitis (0.6%), and ocular manifestations (0.6%). 63, 64 The cumulative incidence of spondyloarthropathy was 5%, 14%, and 22% at 10, 20, and 30 years after UC diagnosis, respectively, 65 and in the IBSEN cohort, 11% of UC patients experienced peripheral arthritis within 6 years after diagnosis, with 20% of these observed before UC diagnosis. 64 Interestingly, risk of hidradenitis suppuritiva may be 6-fold higher in patients with UC, as compared with the general population. 66 Patients with left-sided and extensive colitis may be at increased risk of EIMs as compared with patients with proctitis (15% vs 6%). 63 Other extraintestinal complications. Approximately 20%-24% of patients with UC are anemic at diagnosis, including 8% with severe anemia (<10 g/dL). This rate generally decreases on follow-up to 8%-10% within 5 years and 7% by 10 years, [67] [68] [69] although in a Hungarian cohort, prevalence of anemia was higher at 30% after 7 years of disease. 13 Disease extent and high disease activity (on the basis of elevated CRP or ESR or need for corticosteroids) were significantly associated with anemia. 67, 68 In both Manitoba and Olmsted cohorts, there was no significant increase in risk of fractures in patients with UC, and patients had normal hip and lumbar spine bone density scores. 70, 71 Incidence rate of venous thromboembolism ranged from 1.1 to 2.0/1000 py, with a 5-year and 10-year cumulative probability of 0.8% and 1.2%, respectively, and may be higher in patients with UC, as compared with patients with CD. 72, 73 High disease burden and disease activity, as measured by presence of extensive colitis (OR, 3.3; 95% CI, 1.1-9.4), fulminant colitis (OR, 4.2; 95% CI, 1.3-13.5), and need for corticosteroids (OR, 3.0; 95% CI, 1.0-8.9) as well as smoking (OR, 3.5; 95% CI, 1.1-10.5) were significantly associated with risk of venous thromboembolism. 72, 73 No population-based data on risk of arterial cardiovascular events were available from inception cohorts.
Discussion
We have systematically summarized the current knowledge on the natural history of UC from 17 population-based inception cohorts reported in 60 studies across multiple domains including disease extent, activity, EIMs, medication use, and requirement for surgery. We observed that the diagnosis of UC generally remains stable over time and infrequently evolves into Crohn's disease (<5%). Although left-sided colitis is most frequently observed at diagnosis in approximately 40% of patients, about 10%-30% of patients may develop proximal extension on follow-up. The majority of patients have a mild-moderate course, generally most active at diagnosis and then in varying periods of remission or mild activity; about 10%-15% of patients may experience an aggressive course, and the cumulative risk of relapse is 70%-80% at 10 years. Almost half the patients require UC-related hospitalization at some point during disease course. The 5-and 10-year cumulative risk of surgery in patients with UC is 10%-15%, and although rates of early colectomy have declined, longterm colectomy rates have generally remained stable over time. We observed that almost all patients with UC are exposed to mesalamine within 1 year of diagnosis, although 30%-40% are not on mesalamine on long-term follow-up. About 50% of patients receive corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20%) and anti-TNF (5%-10%). Approximately 1.5% of patients are diagnosed with CRC after 15 years of followup, particularly those with young age at disease onset, extensive disease, and concomitant primary sclerosing cholangitis. Ulcerative colitis is not associated with an increased risk of all-cause mortality. However, gastrointestinal-specific mortality, but not cancerspecific mortality, may be increased. Ulcerative colitis is associated with high morbidity, with high rates of fatigue, inferior health-related quality of life, and high disability, generally comparable with levels observed in patients with CD. Consistent predictors of aggressive UC disease course are young age at diagnosis, extensive disease, early need for corticosteroids, and elevated biochemical markers; achieving mucosal healing early may be strongly associated with a decreased risk of future colectomy. We note that these variables are all easily determined and monitored with electronic medical records and create a future opportunity to risk stratify patients and focus health resource utilization on the subgroup of patients at high risk for a worse disease outcome.
Knowing the UC natural history and identified predictors of disabling disease is essential to initiate personal therapeutic strategy according to risk stratification. High-risk patients may benefit from early combination therapy and low-risk patients from rapid step-up therapy. 76 However, we identified several areas of knowledge gap on natural history of UC. First, although several risk factors associated with a generally aggressive disease course have been identified, an impact of treatment that is based on early stratification of high-and low-risk patients on the natural history of disease is not wellstudied. Second, there are limited data on the course and outcomes of UC in newly industrialized nations and Asia-Oceania region; with the creation of recent population-based cohorts, this knowledge is anticipated to increase in the coming years. Third, contemporary population-based cohorts of patients diagnosed in the biologic era are lacking. These may inform us on the population-level impact of paradigm shifts in approach to UC management during the last decade, such as early use of disease-modifying biologic therapy and treat-to-target strategy. Fourth, slight differences were observed in different outcomes, particularly in risks of surgery and hospitalizations in different cohorts. Whether this is due to differences in medical practices, particularly access to newer therapies, or to true differences in underlying disease behavior and biology in different populations needs to be explored. With creation of large, collaborative population-based networks, these gaps will be bridged in the coming decade.
Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at http://dx.doi.org/10.1016/j.cgh.2017.06.016.
